High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
about
Metalloproteinases: role in breast carcinogenesis, invasion and metastasisInfluence of Immune Myeloid Cells on the Extracellular Matrix During Cancer MetastasisCandidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitorsMolecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironmentLess is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells.Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.Study of matrix metalloproteinases and their inhibitors in prostate cancer.Cancer and the tumor microenvironment: a review of an essential relationship.A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphomaProteases, extracellular matrix, and cancer: a workshop of the path B study sectionMisregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymeraseMembrane associated proteases and their inhibitors in tumour angiogenesis.TIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and Protects Tumor Cells from ApoptosisEndothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivoTissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.Pro-oncogenic cytokines and growth factors are differentially expressed in the post-surgical wound fluid from malignant compared to benign breast lesionsDistinct Transcriptional Changes and Epithelial-Stromal Interactions Are Altered in Early-Stage Colon Cancer DevelopmentStudy of matrix metalloproteinases and their inhibitors in breast cancer.Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse.Growth-stimulatory activity of TIMP-2 is mediated through c-Src activation followed by activation of FAK, PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung adenocarcinoma cellsS100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis.Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival.Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancyTissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells.Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer.Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma.Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.TIMP2 is a Poor Prognostic Factor and Predicts Metastatic Biological Behavior in Gastric Cancer.
P2860
Q24803225-C8D0A017-2AC7-4DF5-B1C9-4383F7680280Q26767150-9EC04996-2144-41F1-BFCE-2652E6FE3091Q26830522-E3642173-B35F-4107-A037-6480CECC50B5Q26865615-751A473F-B1A3-400E-9BCC-89B675FA172AQ30824578-00D1402E-A2E7-47F4-90E7-F4F475C49F85Q30857076-AD89D407-CFDC-4C66-AFE2-758D5726A784Q33708162-72D30061-2D22-433B-AC05-8FB8193A9282Q33806357-3D0A1851-4E32-48F2-995E-5A336AA6CA30Q34210085-D73C416C-6F0B-48DE-8EAD-294D457B4F69Q35097428-7C7554F9-FA9E-4B5B-ABB7-8A32408A91E5Q35271750-D249A085-57AB-4DA2-94B2-10238A21D57FQ35587684-B20A7DAA-99A2-4571-BE4C-4BB8696C379FQ35762042-BEA2DD51-681D-4430-917C-8B1243C60D96Q35791718-38CC12E3-18F6-4409-A5F5-635987EEF9AFQ35842033-B730C71B-F97B-4046-A06E-896D8F233ED7Q36029913-526D3317-4A41-45EF-8B75-C2BE957AF164Q36063498-B5CA7E07-7C60-467E-B87A-702D35D3CC94Q36610142-E7070A1F-528E-4D98-82C5-3E4A69CA7ECBQ36611308-F605692D-05CA-4F6B-BD77-368D05335DC4Q36619063-577E43F2-AFB6-4FD0-9447-6A82E402A5FFQ36673631-6D6FD0AD-3976-429F-86E6-224D5E2D1B6AQ37351433-F5241AEF-4391-4A33-90C0-D414AB8FD4EDQ37465475-A86B2589-A86C-4BF7-895E-A60F5952A9F3Q39689348-33498D25-E83A-4A75-9B08-6ABB9886BDCDQ39833926-6A3D3E0A-3D34-4B91-971C-2A7555189AEAQ43265563-8BB49E5A-A4EA-46C2-AE34-10D564A21C9CQ44131334-8E2977BB-B012-409F-AFB6-4A1719C90436Q44400070-C46E8EF7-9CAA-49E7-9136-57E8237B19EAQ46480579-8C48E70F-466A-4F5C-B8F1-01ADA94540B6Q51366910-9E7762E4-ABEA-49E5-B160-FBA2D5A71ED8Q55472607-9E870662-C474-4A93-BA03-509C67D80F81
P2860
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
@en
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
@nl
type
label
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
@en
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
@nl
prefLabel
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
@en
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
@nl
P2093
P2860
P1476
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
@en
P2093
E McDermott
J M Foidart
K McCarthy
N O'Higgins
P2860
P304
P356
10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8
P577
2000-03-01T00:00:00Z